Drug Trial Radar · NCT01030861
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
Last checked: Nov 20, 2026Latest source record: Aug 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Aug 2010
Primary completion
Nov 2018
Study completion Jun 2019
Sponsor
- Sponsor type
- NIH
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
- First posted
- Dec 14, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy and safety in previous studies; other studies are currently in progress. The results of previous studies indicate that teplizumab reduces the loss of insulin production during the first year after diagnosis in individuals with type 1 diabetes. The purpose of this study is to determine if teplizumab can interdict the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the "pre-diabetic" state and thereby prevent or delay the onset of type 1 diabetes.
Conditions
- Autoantibody Positive
- Non-diabetic Relatives at Risk for Type 1 Diabetes
- High Risk
- Impaired Glucose Tolerance
Interventions
TeplizumabDrug
intravenous infusions
Placebo infusionDrug
Placebo for Teplizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of New Diabetes Per YearTime frame: During follow-up, median 745 days, range 74 to 2683
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
University of California in San Francisco
San Francisco, California
University of California-San Francisco
San Francisco, California
Stanford University
Stanford, California
Barbara Davis Center for Childhood Diabetes/ University of Colorado
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
University of Florida
Gainesville, Florida
University of Miami
Miami, Florida
University of South Florida
Tampa, Florida
Indiana University
Indianapolis, Indiana
University of Minnesota
Minneapolis, Minnesota
The Children's Mercy Hospital
Kansas City, Missouri
Columbia University
New York, New York
University of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University
Nashville, Tennessee
University of Texas
Dallas, Texas
Baylor College of Medicine
Houston, Texas
Benaroya Research Institute
Seattle, Washington
The Hospital for Sick Children
Toronto, Ontario, Canada
Forschergruppe Diabetes
Munich, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.